Latest News

Q2 2023 Watch: Braidwood decision impacts PrEP coverage; ADAP coverage analysis and Medicaid program updates.

Biden FY2024 budget includes $9.7B PrEP program and $11B Hepatitis Elimination Program.

HCV Medicaid Access dashboard 2023 update: progress in eliminating treatment restrictions by state.

Q1 2023 Watch: Tennessee rejecting federal HIV funding; updates on ADAPs, Medicaid, veterans care, and harm reduction.

Nevada expands syringe vending machines with naloxone, fentanyl strips; anonymity critical for uptake.

Q4 2022 Watch: HHS renewed opioid emergency; CANN launched monkeypox project; HEPLISAV-B hepatitis B vaccine covered.

Louisiana and Washington HCV subscription models save millions but fail elimination goals; cost alone isn't the barrier.

Monitoring report documents HCV treatment access challenges across ADAP, Medicaid, and VA systems.

Only 35% of privately insured and 23% of Medicaid patients initiate HCV treatment due to payer barriers.

Q3 2022 review of HCV drug access across ADAPs, Medicaid, and comprehensive harm reduction programs.

Community-based low-barrier HCV treatment for PWID significantly improves liver health outcomes.

Q2 2022 Watch reviewing HCV treatment access across ADAPs, Medicaid, Veterans benefits, and assistance programs.

STI and HCV rates rise despite reduced screening, reflecting chronic public health underfunding.

Medicaid sobriety restrictions on HCV treatment contradict harm reduction and elimination goals.

Access Health Louisiana uses animated series and radio to educate communities on HIV, HCV, and public health.

Q1 2022 assessment of HCV treatment access in ADAPs and Medicaid with DAA coverage and harm reduction data.

CANN announces 2022 organizational changes including rebranding and launching the 340B Action Center.

CANN reflects on 2021 advocacy spanning 340B drug pricing, HIV, hepatitis C, and substance use disorder policy.

FDA reclassifies HCV testing to reduce regulatory burden and enable new test makers to enter market.

Q4 2021 Watch covering HCV drug formulary updates, ADAP and Medicaid changes, and pandemic impact on care.